摘要
目的观察芪白平肺胶囊对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)大鼠细胞因子的影响,探讨芪白平肺胶囊防治COPD的作用机制。方法 SD大鼠随机分成正常组、模型组、芪白平肺胶囊(0.72,1.44,2.88 g·kg?1)组和固本咳喘片(1.44 g·kg?1)组。除正常组外,其余各组采用复合因素复制COPD大鼠模型。于造模第1天起,给药组分别灌胃给予相应的受试药物,正常组和模型组给予等量溶媒,疗程为4周。实验结束后,测定大鼠血清白细胞介素(IL)-8、肿瘤坏死因子(TNF)-α含量,同时取固定部位肺组织,HE染色观察组织病理学改变,免疫组化技术测定肺组织中细胞间黏附分子(ICAM)蛋白的表达,RT-PCR技术测定肺组织中TNF-αmRNA的表达。结果与模型组相比,芪白平肺胶囊(1.44,2.88 g·kg?1)不仅可减轻COPD大鼠病理组织学损伤程度,还可明显抑制IL-8、TNF-α、ICAM的表达。结论芪白平肺胶囊对COPD大鼠具有一定的保护作用,其机制可能与下调促炎因子,减轻气道炎症有关。
OBJECTIVE To investigate the effects of Qibai Pingfei capsules on the expression of cytokines in rats with chronic obstructive pulmonary disease(COPD) and to explore its possible mechanisms. METHODS The rats were randomly divided into six groups, including normal group, COPD model group, Qibai Pingfei capsules (0.72, 1.44, 2.88 g·kg-1) treated groups and Guben Kechuan tablets (1.44 g·kg-1) group. Complex factors were used to make COPD model and at the same time Qibai Pingfei capsules were used daily via lavage for 4 weeks. The interleukin (IL)-8, tumor necrosis factor (TNF)-α level in serum were determined by radioimmunity, lung samples were taken to examine the degree of COPD by HE stain and immuninochemistry of ICAM. Moreover, TNF-α mRNA expression was detected by RT-PCR technology. RESULTS Compared with the model group, Qibai Pingfei capsules (1.44, 2.88 g·kg-1) treated groups not only significantly reduced histopathological change, but also effectively prevent the level of IL-8, TNF-α, ICAM. CONCLUSION The protective effect in COPD rats of Qibai Pingfei capsules may be associated with its action of alleviate the airway inflammation by controlling the level of IL-8 and TNF-α.
出处
《中国现代应用药学》
CAS
CSCD
2014年第4期397-401,共5页
Chinese Journal of Modern Applied Pharmacy
基金
国家中医药管理局重点学科中医肺病学科开放基金(2011fbxk016B)